GGHC
PRQR icon

Gilder Gagnon Howe & Co’s ProQR Therapeutics PRQR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-96,993
Closed -$359K – 257
2022
Q4 		$359K Sell
96,993
-26
-0% -$34 0.01% 225
2022
Q3 		$72K Sell
97,019
-808
-0.8% -$649 ﹤0.01% 247
2022
Q2 		$76K Sell
97,827
-24
-0% -$18 ﹤0.01% 249
2022
Q1 		$89K Sell
97,851
-1,281,272
-93% -$4.29M ﹤0.01% 288
2021
Q4 		$11M Buy
1,379,123
+226,211
+20% +$1.72M 0.06% 172
2021
Q3 		$9.65M Buy
1,152,912
+634,179
+122% +$4.14M 0.05% 203
2021
Q2 		$3.5M Buy
+518,733
New +$3.34M 0.02% 278

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Gilder Gagnon Howe & Co's PRQR Position: Q1 2023 in Review

Gilder Gagnon Howe & Co sold out of ProQR Therapeutics (PRQR) in Q1 2023, closing a stake of 96,993 shares — an estimated $359K sold.

Gilder Gagnon Howe & Co first reported a position in PRQR in Q2 2021 and held it in 7 quarters. The position peaked at $11M in Q4 2021. 55 funds tracked by Wall St. Rank hold PRQR as of Q1 2023.

  • Gilder Gagnon Howe & Co reported no remaining ProQR Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 96,993 ProQR Therapeutics shares in Q1 2023, an estimated $359K.
  • Gilder Gagnon Howe & Co first reported a position in ProQR Therapeutics in Q2 2021 and held it in 7 quarters.
  • Gilder Gagnon Howe & Co's ProQR Therapeutics position peaked at $11M in Q4 2021.
  • 55 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2023, filed 15 May 2023.